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Abstract
Background: Improvement of patient quality of life is the ultimate goal of biomedical research, particularly when dealing
with complex, chronic and debilitating conditions such as inflammatory bowel disease (IBD). This is largely dependent on
receiving an accurate and rapid diagnose, an effective treatment and in the prediction and prevention of side effects and
complications. The low sensitivity and specificity of current markers burden their general use in the clinical practice. New
biomarkers with accurate predictive ability are needed to achieve a personalized approach that take the inter-individual
differences into consideration.
Methods: We performed a high throughput approach using microarray gene expression profiling of colon pinch biopsies
from IBD patients to identify predictive transcriptional signatures associated with intestinal inflammation, differential
diagnosis (Crohn’s disease or ulcerative colitis), response to glucocorticoids (resistance and dependence) or prognosis (need
for surgery). Class prediction was performed with self-validating Prophet software package.
Results: Transcriptional profiling divided patients in two subgroups that associated with degree of inflammation. Class
predictors were identified with predictive accuracy ranging from 67 to 100%. The expression accuracy was confirmed by real
time-PCR quantification. Functional analysis of the predictor genes showed that they play a role in immune responses to
bacteria (PTN, OLFM4 and LILRA2), autophagy and endocytocis processes (ATG16L1, DNAJC6, VPS26B, RABGEF1, ITSN1 and
TMEM127) and glucocorticoid receptor degradation (STS and MMD2).
Conclusions: We conclude that using analytical algorithms for class prediction discovery can be useful to uncover gene
expression profiles and identify classifier genes with potential stratification utility of IBD patients, a major step towards
personalized therapy.
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Introduction
Crohn’s disease (CD) and ulcerative colitis (UC), the two main
clinical forms of IBD, are chronic relapsing inflammatory
disorders of the gastrointestinal tract resulting from an inappro-
priate and continuous inflammatory response to commensal
microbes in genetically susceptible hosts, although the exact
etiology remains unknown [1]. CD and UC are distinct but
heterogeneous entities, frequently showing overlapping symp-
toms/features with systemic and extra-intestinal complications
that render the diagnosis difficult and inaccurate. Furthermore,
the degree of heterogeneity within both forms of IBD is also high,
and patients with the same diagnosis, i.e. CD or UC, may have
markedly different outcomes. Most importantly, the response to
therapy cannot be predicted at diagnosis and therapeutic
approaches are individualized according to the symptomatic
response and tolerance to medical intervention. Previous attempts
to identify prognostic markers have focused on clinical factors that
lack specificity and, hence are not clinically useful [2]. In the
absence of unique biomarkers of disease activity, severity is
established based on clinical parameters, systemic manifestations,
and the global impact of the disease on the patient’s quality of life
[3]. Therapeutic options are determined by assessing disease
location, severity, and extra-intestinal complications. Therapy
approaches are based on either a ‘‘step-up’’ management strategy
by increasing immunosuppression or a ‘‘top-down’’ alternative
with the early use of anti-TNF-alpha treatment. In both cases,
economic and safety concerns exist regarding the indiscriminate
use of these strategies due to the elevated cost of anti-TNF-alpha
treatment, potential unnecessary immunosuppression, life-threat-
ening side-effects and long-term sequelae of drug treatment [4].
PLOS ONE | www.plosone.org 1 October 2013 | Volume 8 | Issue 10 | e76235
As a consequence of the heterogeneity of IBD patients, a
comprehensive evidence-based search of novel biomarkers for an
appropriate patient stratification that account for the inter-
individual differences in severity, drug efficacy, side effects or
prognosis would help guide clinicians in the management of
patients with IBD and represent a major step towards personalized
medicine. Although immunological markers like anti-Saccharomyces
cerevisiae antibodies or genetic variants of NOD2 are statistically
associated with prognosis of surgical intervention in IBD [5], these
markers often lack sensitivity or are not frequent enough to be
clinically useful. The search of new biomarkers of IBD course can
benefit from molecular approaches like gene expression profiling
[6], which has successfully been used and translated into clinical
practice. Van de Vijver et al discovered a 70-genes prognosis
classifier of the clinical outcome of breast cancer patients [7]. In
ovarian cancer, Bonome et al defined a predictor gene set of
survival [8]. With the same strategy, Mckinney et al identified a
gene expression signature with prognosis predictor value for
antineutrophil cytoplasmic antibodies-associated vasculitis [9].
These studies reflect the intense effort on the development of
new tools and algorithms that go far beyond the classical selection
of a number of up- or down- regulated genes to reliably translate
mathematical and statistical analyses into biological meaning.
Accordingly, we tested a novel analytical approach [10] to study
the gene expression signature of intestinal tissues from IBD
patients aiming at identifying new candidate prognostic genes
associated to clinically relevant parameters. We hypothesized that
correlation with clinical prognostic parameters may group samples
with similar gene expression profiles and help identify potential
biomarkers useful for IBD stratification with higher reliability.
Methods
Ethics statement
Individuals were recruited either at Hospital Santa Creu i Sant
Pau (Barcelona, Spain) or at the University of Illinois Hospital
(Chicago, IL) after a written informed consent was obtained. The
Institutional Review Board of the University of Illinois at Chicago
and the Comité Ético de Investigación Clı́nica del Hospital Santa
Creu i Sant Pau approved the protocols.
Patients
For this study we enrolled 15 patients with an established
diagnosis of ulcerative colitis, 13 patients with Crohn’s disease and 7
healthy individuals with a normal colon referred for colorectal
cancer screening. Disease activity was assessed based on parameters
such as: abdominal pain, bowel consistency and frequency, blood in
stool, nausea/vomiting, constitutional symptoms, extracolonic
manifestations, presence of abdominal mass, blood inflammatory
markers, and colonic biopsy results. Other data collected includes:
age at diagnosis, disease extension, disease-related surgery, tobacco
consumption, co-morbidities, medications, and need of or response
to immunomodulators (Azathiopurine or 6-Mercaptopurine), In-
fliximab, and glucocorticoids. A summary of these data is shown in
Table S1. Patients were classified as glucocorticoid-dependent when
they responded to glucocorticoids but experienced loss of clinical
response when glucocorticoids were tapered to less than 30 mg/day
or less, or relapse within the first 3 months after glucocorticoids are
stopped. Patients were classified as glucocorticoid-resistant when
there was a lack of meaningful clinical response to glucocorticoids
up to doses of prednisone 1 mg/kg/day (or equivalent) within 30
days for oral therapy or 7 days for IV therapy. Patients were
purposefully selected for this study to represent different clinical
phenotypes.
Isolation of RNA and microarray hybridization
Four endoscopic pinch biopsies of macroscopically un-inflamed
mucosa were taken from ascending colon. One biopsy was fixed in
4% buffered formaldehyde. Total RNA was extracted from three
pooled biopsies using the RNeasy Micro kit (Qiagen, Crawley,
UK). All sample labeling, hybridization, staining and scanning
procedures were carried out using Affymetrix standard protocols
and equipment (Affymetrix, Santa Clara, CA). Briefly, double-
stranded cDNA was synthesized from 2mg of total RNA using the
One-Cycle cDNA Synthesis kit. In vitro transcription was
performed using the IVT Labelling kit and the cRNA obtained
was checked for quality and purified with the GeneChip Sample
Cleanup Module. 15mg of cRNA were fragmented and hybridized
on Human Genome U133 plus 2.0 arrays for 16 hours at 45uC.
Arrays were then washed and stained with streptavidin-phycoer-
ythrin and images scanned and analyzed with Affymetrix
GeneChip Command Console (AGCC 1.1). Spike controls (BioB,
BioC, BioD and Cre) were used as quality controls. Following
MIAME recommendations, microarray data were deposited in
Gene Expression Omnibus database (accession number
GSE36807) where protocols, normalization methods and original
raw data are publicly available.
Data normalization, filtering and clustering
Bioconductor software version 2.15 was used for data normal-
ization (affyPLM package, RMA method) and quality controls (%
present genes, average background, scale factor GAPDH 3’/5’
ratio and spike-in controls; simpleAffy package). Data analysis and
filtering were made with Spotfire DecisionSite v9.0. Normalized
intensity values were used to obtain the fold change values,
calculating the log2 of the ratio [average of the cases replicates/
average of the control replicates]. Genes with a fold change .1 or
,21 and p,0.05 (t-test) were considered differentially expressed.
Hierarchical clustering (Unweighted Pair Group Method with
Arithmetic Mean and Euclidean distance similarity measure) and
principal component analysis were also performed with Spotfire
DecisionSite v9.0.
Functional analysis and predictor discovery
Functional analyses of differentially expressed genes were made
using Panther Classification System v6.1 [11]. We used the tool
Prophet [10] to find the optimal subset of genes that best
distinguish between the experimental groups, the class predictor
genes. Predictors were built with the 54,675 probes contained in
the microarray. Briefly, the software randomly divides the data in
partitions, chooses one partition as training test set and builds
several predictors whose efficiency is checked with the training set
at a time. The random splitting of samples significantly increases
predictive accuracy and self-validates the results. This process is
repeated as many times as the number of partitions. Then the
error is calculated for each of these predictors and, finally, the
smallest set of genes that results in the smallest error is reported.
The F ratio test was selected for the ranking of genes. The five
algorithms implemented in Prophet were tested in all comparisons:
support vector machine, k-nearest neighbor, diagonal linear
discriminant analysis (DLDA), self-organizing maps and nearest
shrunken centroids. DLDA generated predictor sets with the lower
classification error rates. A leave-one-out cross-validation strategy
was performed to find the best predictor with the optimal number
of genes.
Predictor Biomarkers of Inflammatory Bowel Disease
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Quantitative real time-PCR validation
cDNA was synthesized using 1mmg of total RNA with the
SuperScript III Reverse Transcriptase (Invitrogen, Paisley, UK).
Real time-PCR was performed with 200 ng of cDNA per well and
Power SYBR Green PCR Master Mix (Applied Biosystems,
Warrington, UK), using the ABI Prism 7900HT Sequence
Detection System. The full list of Quantitect primers (QIAGEN,
Crawley, UK) used is reported in Table S2. Dissociation step was
included to confirm the absence of un-specific products. Data
(n = 3) is reported as DCt using GAPDH as endogenous control.
Statistical analysis
Microarray data was analyzed using t-test. Clinical data was
analyzed by Fisher’s exact test or Chi-square test for trend when
appropriate. Real time-PCR was analyzed by Pearson correlation
and linear regression tests. Predictors were analyzed by two-way
ANOVA. In all cases p,0.05 was considered statistically
significant.
Results
Microarray data analysis groups high and low
inflammation subclasses of CD and UC patients
An unsupervised hierarchical clustering using all genes
represented in the chip was run in order to cluster the 35
subjects on the basis of their similarity and assess the degree of
heterogeneity among samples. Although healthy samples seem to
cluster together, the variation in gene expression patters in CD
and UC was more complex, underlining the high degree of
heterogeneity within IBD samples (Figure 1A). It is usually
presumed that relatively few genes may distinguish between
classes, and hence the differences between groups can be masked
when using a whole genome clustering approach, as the vast
majority of them would remain unchanged. Therefore, in order
to study the heterogeneity within CD and UC patients, we
performed a hierarchical clustering using the differentially
expressed genes between CD and UC compared to healthy
controls (261 and 1255 probes respectively). Surprisingly, in both
cases samples were stratified in two distinct patient subgroups
(Figure 1B) that were defined CD1 and UC1 as ‘‘Low
Inflammation’’ subtypes and CD2 and UC2 as ‘‘High Inflam-
mation’’ subtypes on the basis of the following findings.
Functional annotation of the genes reveals up-regulation on
metabolism or transport genes in the subgroups so-called CD1
and UC1, while up-regulation of predominantly inflammatory
genes in the groups designated as CD2 and UC2. Principal
component analysis (Figure 1C) also discriminated between the
subgroups identified, and the association of these subgroups with
clinical features further relates CD2 and UC2 with higher degree
of disease activity (Figure 1D). Detailed clinical data is reported in
Table S1. The number of differentially expressed genes between
groups (Figure 1E) suggests an association between ‘‘more
disease’’ profile with CD2 and UC2 as the number of altered
genes for CD1 and UC1 respect to healthy controls was 347 and
287 probes respectively, but 1,324 for CD2 and 2,590 for UC2.
The low number of differentially expressed genes between CD
and UC (389) and between CD2 and UC2 (only 79) was truly
striking, emphasizing the close pathogenic nature of CD and UC.
The top 10 up- and down-regulated genes between CD1 vs. CD2
and UC1 vs. UC2 are reported in Table S3.
Class-predictor analysis identifies sets of genes that
discriminate between high and low inflammation
subgroups of CD and UC
In order to discover new biomarkers related to the degree of
intestinal inflammation we used the software package Prophet to
identify the subset of genes that best discriminated CD1 from CD2
and UC1 from UC2, i.e. a predictor classifier of high and low
inflammation activity. We searched for the smallest list of genes to
accurately classify patients into their respective subgroups. Figure
2A shows the results from the cross-validation analysis. In the case
of CD, there was a set of 5 genes that predicted if a sample
belonged to group CD1 or CD2 with 92% accuracy. Interestingly,
most of the predictors for UC had an accuracy of 100%. The
expression of the genes included in the selected predictors (Figure
2B), was investigated in the public microarray repository GEO
database. As shown in Table S4 the gene expression changes
follow the same trend reported in other microarray experiments.
Using this approach, previous reports confirmed the utility of class-
predictor identification by running more microarray analysis in
new patients [7]. However, the translation of these findings into
clinical practice would require a more accessible technique than
microarray profiling, such as quantitative real time-PCR. There-
fore, a total of 42 genes (Table S2) were selected to analyze the
general agreement between our microarray and PCR data. The
correlation between both techniques was found to be optimal
(Figure 3) with a correlation of 84% and 91% for CD and UC
respectively. Then, to validate our predictors by using PCR data
instead of microarray data, we performed the predictor analysis
using Prophet and available primers (see Table S2). The results
showed exactly the same degree of predictor accuracy (CD1 vs.
CD2, 92.3%; UC1 vs. UC2, 100%) as obtained with microarray
data. These data suggest that real time-PCR analyses performed
on microarray-based predictors can replicate the results with
similar accuracy and hence can be a simple, economical and
reliable approach for the analysis of class predictors.
Identification of new predictor genes associated with
clinical parameters and IBD phenotypes
Once our approach had been validated, we focused on
identifying new biomarkers related to relevant clinical parameters
of IBD. Patients were classified according to glucocorticoid (GC)
sensitivity, GC-dependency, IBD phenotype, if they had suffered
IBD-related intestinal surgery or if they show high or low
inflammation phenotype according to their gene expression
profile. The statistical association among these subgroups of
patients is shown in Figure S1. No significant association was
observed among the different groups except for GC-sensitivity that
was significantly associated with need of surgery and degree of
inflammation. This result is not surprising because GC-resistance
is usually associated with worse outcome and increased risk for
surgery. Figure 4 summarizes the best sets of genes (i.e. sets with
the fewest number of genes and the lowest prediction error) found
to correctly classify patients according to GC-sensitivity (Figure
4A, 35 genes, 82% accuracy), GC-dependence (Figure 4B, 10
genes, 82% accuracy) and need of intestinal surgeries (Figure 4C,
10 genes, 79% accuracy). Two-way ANOVA with Bonferroni
multiple testing correction was performed to assess if the difference
in gene expression between the groups was significant. All genes
showed a p value lower than 0.01.
In the next step, we used this new approach to build predictor
classifiers that would potentially aid in the accurate diagnosis of
IBD. We built 5 different predictor classifiers performing the
following comparisons: IBD (i.e. CD and UC) vs. H (healthy
Predictor Biomarkers of Inflammatory Bowel Disease
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controls), CD vs. H, UC vs. H, CD vs. UC, CD1 vs. UC1 and CD2
vs. UC2. Figure 5 summarizes the best sets of genes found to
correctly classify patients between these groups. The predictor
classifiers of IBD forms vs. healthy samples showed the highest
accuracy (.90%) but it dropped to 79% (CD vs. UC), 85% (CD1
vs. UC1) and 68% (CD2 vs. UC2). This result underlines the high
similarity of both conditions at the gene expression level. The best
predictor of CD vs. UC consisted of 5 genes with a prediction error
of 21% (Figure 5D). A set of 10 genes was found to be the best
predictor between the ‘‘High Inflammation’’ subgroups (CD2 and
UC2) although the prediction error increased to 33% (Figure 5F).
The lowest prediction error (15%) was obtained with ‘‘Low
Inflammation’’ samples, i.e. CD1 vs. UC1 (Figure 5E). Interest-
ingly, more than one probe for the same gene was identified in
several predictor sets, a fact that may increase the significance of
that particular gene as a potential biomarker. This was the case for
the genes that encode for pleiotrophin (PTN), copine VIII
(CPNE8), NAD(P)H dehydrogenase quinone 2 (NQO2) and
EFR3 homolog A (EFR3A). OLFM4 and PTN were up-regulated
in the predictor set that discriminated healthy controls from UC
and CD patients (Figure 5A-C) (Figure 5D-F), suggesting a
common biological role for OLFM4 and PTN in both forms of
IBD. NQO2 and CPNE8 were identified as classifiers that
discriminate CD vs. UC and CD1 vs. UC1 (Figure 5D and E),
suggesting a potential utility as biomarkers for IBD diagnosis.
Discussion
The ability to predict an individual’s clinical course is probably
one of the major causes for concern for IBD patients, as it implies
the appropriate choice of therapeutic tools. The response to
therapy cannot be predicted at diagnosis and therapeutic
approaches are individualized according to the symptomatic
response and tolerance to medical intervention. Although existing
serologic and fecal biomarkers can help diagnose and guide
therapeutic choices [5] sensitivity, specificity and overall usefulness
Figure 1. Discovery of Crohn’s disease (CD) and ulcerative colitis (UC) inflammatory subtypes by gene expression profiling. (A)
Unsupervised hierarchical clustering of UC (blue), CD (red) and healthy controls (green) cases using the 54,675 probes contained in the chip. Up-
regulated genes are shown in red and down-regulated genes in green. (B) Supervised hierarchical clustering of CD cases or UC cases using
differentially expressed genes between CD and healthy (261 probes) and UC and healthy (1255 probes) respectively. This process defined two
subgroups for both CD and UC cases. Functional analyses were performed using PANTHER Classification System. Examples of genes of each category
are shown. (C) Clustering of samples using principal component analysis: CD1 (pink), CD2 (red), UC1 (light blue), UC2 (dark blue), healthy controls
(green). (D) Association between clinical characteristics and CD and UC subtypes. Data represents the proportion of patients of each disease subtype
included in different clinical variables, *p,0.05, Fisher exact test, CD1 vs. CD2 or UC1 vs. UC2. Complete clinical data is provided in Table S1. (E)
Number of differentially expressed genes (p,0.05, t-test) in different comparisons among groups and with a fold change .1 or ,21.
doi:10.1371/journal.pone.0076235.g001
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Figure 2. Identification of predictive classifiers of ‘‘High’’ and ‘‘Low’’ inflammation subtypes of Crohn’s disease (CD) and ulcerative
colitis (UC). (A) A class predictor was built for both CD and UC using the tool Prophet and the 54,675 probes contained in the chip, using the leave-
one-out cross-validation strategy. For each predictor, patients that were correctly classified are shown green, while those patients that the predictor
failed to classify correctly are shown in red. (B) Based on the accuracy of each classifier, a 10-gene predictor was selected in both cases, which were
able to accurately classify 92% of CD patients and 100% of UC patients. Up-regulated genes are shown in red and down-regulated in blue.
doi:10.1371/journal.pone.0076235.g002
Figure 3. Confirmation of the predictive classifiers of ‘‘High’’ and ‘‘low’’ inflammation subtypes of Crohn’s disease (CD) and
ulcerative colitis (UC) by quantitative real time-PCR. A total of 43 genes (including the predictors) were selected for real time-PCR validation of
the microarray data in CD (A) and UC (B). Scatter plots show the correlation between microarray (fluorescence intensity, FI) and PCR (DCt value
respect to the endogenous GAPDH, DCt) data, validating microarray results. The tables show the predictions obtained with the selected set of genes
obtained from the microarray analysis using the PCR data. For each predictor, patients that were correctly classified are shown in green while those
patients where the predictors failed to classify are shown in red. The classification accuracy obtained with PCR data was the same as the one obtained
with the microarray data.
doi:10.1371/journal.pone.0076235.g003
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are not well established and their application in patient
stratification is still debated. From the genetic perspective, a
number of genetic markers have been associated with several
clinical features, but to date, only the thiopurine S-methyltrans-
ferase genotyping test to assess toxicity of thiopurine has been
translated into IBD clinical practice [12].
Whereas gene expression profiling has been successfully used to
predict metastasis and response to chemotherapy in oncology, they
have generally not detected signatures with equivalent prognostic
value in IBD and low, if any, inter-translational coincidence
between their transcriptional signatures can be found. Heteroge-
neous results may be due to confounding factors such as disease
heterogeneity, racial lineage, variability in sample location,
extraction procedure, cellular composition and differences in
microarray platform and normalization algorithm. Despite these
difficulties, efforts to reduce sample variability and the application
of new tools and algorithms, that go far beyond the classical
selection of a number of up- or down-regulated genes, to provide a
small set of classifier genes may reliably translate mathematical
and statistical analyses into clinical practice [13]. Indeed, Lee et al
recently identified a classifier set of genes that predict prognosis in
IBD patients [14]. CD and UC patients were stratified into two
subgroups on the basis of CD8+ T cell gene expression profiling
which correlated with the course of the disease.
Using the same strategy of class prediction, we set out to explore
whether whole-gene expression profiling may provide clinically
relevant biomarkers for IBD. This hypothesis aims at the selection
of the smallest set of genes that accurately classified IBD subgroups
using new in silico analyses. As in Lee et al [14], a hierarchical
clustering of our IBD patients identified 2 distinct populations
within CD and UC patients on the basis of their gene expression
profile, which correlated with the degree of inflammation
according to our functional analysis, clinical data and differentially
expressed genes associated to each subgroup. It is interesting that
our data confirm the existence of this gene expression signature
associated with a more aggressive disease behavior. Our strategy
was validated with the identification of the smallest set of genes
that best discriminated between high (CD2, UC2) or low (CD1,
UC1) inflammation phenotypes. A predictor set of 5 genes was
identified that classified CD patients into high or low inflammation
phenotypes with 92% of samples correctly classified. The positive
and negative predictive values were 100 and 88% respectively;
sensitivity was 80% and specificity 100%. In the case of UC, a 10-
gene set was also identified as predictive for UC patients, with
Figure 4. Systematic search for new predictors associated with clinical variables. Predictors were built using the tool Prophet and the
54,675 probes contained in the microarray, using the leave-one-out cross-validation strategy, to identify classifiers genes for glucocorticoid sensitivity
(A), glucocorticoid dependency (B) or need for surgery (C). Data are represented as box and whiskers plots, where the error bars designate the
smallest and largest observations and dots designate the outliers. Data was analyzed by two-way ANOVA followed by Bonferroni post test, p values
higher than 0.05 were considered not significant (ns), *p,0.01, **p,0.001.
doi:10.1371/journal.pone.0076235.g004
Predictor Biomarkers of Inflammatory Bowel Disease
PLOS ONE | www.plosone.org 6 October 2013 | Volume 8 | Issue 10 | e76235
Predictor Biomarkers of Inflammatory Bowel Disease
PLOS ONE | www.plosone.org 7 October 2013 | Volume 8 | Issue 10 | e76235
100% sensitivity and specificity. Notably, none of these genes was
found among the top up- or down-regulated genes with fold
change (.1 or ,21) and p-value (,0.05). This observation
indicates that the classical approach of selecting a list of
differentially expressed genes for classification studies in IBD
may not be appropriate and possibly explain the lack of success in
defining and validating biomarkers. We also observed that, rather
than a big difference (i.e. in fold change), the consistency among
samples may be a more relevant parameter to identify a good
biomarker, as most of the predictors discovered in this work
showed a p value ,0.001 despite a modest fold change. Equally
important for a good biomarker is that it can be easily measured.
We quantified the expression of 42 selected genes (including those
in the predictor sets) in the 35 subjects included in this study (i.e.
more than 1,400 measurements). The correlation between real
time-PCR and microarray data was highly concordant (84% and
92% for CD and UC, respectively). This observation validated the
accuracy of the gene expression data in our experimental
procedure.
The high/low inflammation predictors can be informative and
provide clues to IBD pathogenesis. Our aim, however, was to
identify clinically relevant predictor genes to classify patients
according to GC-sensitivity, GC-dependence, need for surgery
and diagnosis. We successfully identified gene panels that
discriminate between these conditions. In view of the potential
heterogeneity and complexity of the mechanisms contributing to
GC response and its potential impact on the natural history of
IBD, it is noteworthy that pathway analysis identified autophagy
and endocytosis processes in the 35 genes set of GC-sensitivity
predictor (sensitivity and specificity of 33% and 95% respectively).
ATG16L1 along with other 5 genes are involved in endocytosis
processes (DNAJC6, VPS26B, RABGEF1, ITSN1 and
TMEM127). ATG16L1, a reported susceptibility gene for IBD,
controls autophagy, a crucial process in the resistance against
infection and removal of intracellular microbes. Interestingly,
Bonapace et al found that activation of autophagy was able to
resensitize GC-resistant leukemia cells [15]. Accordingly,
ATG16L1 was down-regulated in GC-resistant patients, which
might lead us to speculate that induction of autophagy might help
to overcome GC-resistance in IBD patients, as it happens in
leukemia. Other genes encoding for steroid sulfatase (STS) and
MDM2 oncogene E3 ubiquitin protein ligase, both involved in the
proteosomal degradation of the GC receptor [16], may also play a
role in the mechanisms leading to GC-resistance. CD36 and
LILRA2 (leukocyte immunoglobulin-like receptor, subfamily A
with TM domain, member 2) were included in the predictor set for
need of surgery (sensitivity and specificity of 50% and 85%
respectively). Deficiency of CD36 scavenger receptor, mainly
expressed in macrophages, has been associated with a more
aggressive colitis in mice [17]. LILRA2 up-regulation is also worth
mentioning as this protein induces cytokine production by
monocytes while reducing their phagocytic ability [18] and
correlates with disease severity in rheumatoid arthritis [19]. The
best predictor from our study was able to distinguish IBD from
healthy subjects with 97% accuracy with only 5 probes (sensitivity
and specificity of 100% and 86% respectively), 2 of them
representing the gene PTN (pleiotrophin) which has already been
described to be down-regulated in CD patients [20]. Pleiotrophin
controls several processes such as angiogenesis or cell proliferation
but it also exerts strong antibacterial activity [21], suggesting
another innate immune mechanism deregulated in IBD. The same
accounts for the glycoprotein olfactomedin 4 (OLFM4), up-
regulated in both forms of IBD according to our data, that is
secreted into mucus [22] and acts by inhibiting immune responses
against Helicobacter pylori, hence contributing to the persistence of
infection by a mechanism involving NOD1 and NOD2 [23].
Another ramification of our study was to identify predictor sets
that would discriminate between CD and UC. The accuracy
dropped when we built predictor sets to discriminate between CD
and UC. While this result may appear unsatisfactory, the
predictive capacity of our predictor sets (Figure 5 D-E-F, from
68% to 84%) is at the level of those proposed by Hakonarson et al
to predict GC response in asthma patients [24]. Indeed, prognosis
in patients with CD and UC was proposed on the basis of
predictor signatures with 59% (CD) and 77% (UC) sensitivities
[14]. The fact that the comparison of low inflammation groups
CD1 vs. UC1 yielded better predictors than high inflammation
groups CD2 vs. UC2 suggests that the inflammatory process at
active stages is a natural confounding factor that limits the ability
of the predictor set. In this case, gene expression analysis of
predictor genes in patients in remission may therefore be
preferential for a better diagnosis of IBD.
In summary, we show here that gene expression profiling can be
successfully used to stratify patients and identify transcriptional
signatures associated with clinical parameters. We identified
several predictor gene panels that contained genes involved in
immune mechanisms (PTN, OLFM4, LILRA2, CD36), autoph-
agy or GC response (STS, MDM2). This represents, to our
knowledge, the first biomarker discovery based on specifically
designed analytical algorithms with potential value to predict GC
response and need of surgery as well as with diagnostic value for
IBD patients. This could therefore enable patients to be classified
and receive personalized therapy according to the expression level
of predictor genes. Our study is the first stone in the validation of
the potential use of our class predictors in larger cohorts of IBD
patients.
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disease, CD (B), ulcerative colitis, UC (C), CD vs. UC (D), low inflammation subtypes of CD and UC (E), and high inflammation subtypes of CD vs. UC (F).
Data are represented as box and whiskers plots, where the error bars designate the smallest and largest observations and dots designate the outliers.
Data was analyzed by two-way ANOVA followed by Bonferroni post test, p values higher than 0.05 were considered not significant (ns), *p,0.01,
**p,0.001.
doi:10.1371/journal.pone.0076235.g005
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